Canadian R&D Spending Up
Member companies of the Pharmaceutical Manufacturers Association ofCanada, which represents the research-based industry, spent a total of C$768.7 million ($556.6 million) on R&D in 1996, compared with C$623.9 million in 1995, reports the association.
The PMAC noted that this represents around 15.7% of company sales on average, and which is a significant improvement on the average 12% level at which R&D spending in Canada had stood for a number of years.
Quebec Seeks Patent Extension Meantime, the provincial government of Quebec has asked Canada's federal government in Ottawa to give developers of innovative prescription drugs a guaranteed 15 years' exclusive sales. The federal government is currently examining drug patent legislation (Marketletters passim) and is due to announce amendments in the third quarter of the year.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze